A potential ‘game changer’ for eye disease

November 8, 2016

By Jan Jarvis

katalin-prokai-tatrai
An eye drop that could prevent blindness caused by glaucoma is one step closer to becoming a reality.

A novel pharmacological intervention to control retinal ganglion cell death caused by glaucoma is in preclinical development, said Katalin Prokai-Tatrai, PhD, Associate Professor in the Center for Neuroscience Discovery and the Department of Pharmaceutical Sciences in the UNT System College of Pharmacy.

“We believe that this novel therapeutic intervention will be effective for other blinding eye diseases associated with neurodegeneration, such as age-related macular degeneration,” said Dr. Prokai-Tatrai. “We are very hopeful we will generate data that shows we can prevent and stop the damage that leads to blindness.

“If it works, it will be a game-changer in terms of how neurodegenerative eye diseases are treated.”

The five-year study is funded by a $2.1 million grant from the National Eye Institute at the National Institutes of Health.

Initially the study will target the effectiveness of the drug for glaucoma, the second-leading cause of blindness. The study will then be expanded to treat other neurodegenerative diseases impacting the brain.

“The beauty of our drug is that it remains inactive until it reaches the retina when applied in eye drops,” Dr. Prokai –Tatrai said.

Scientists know that glaucoma is caused by elevated pressure, but the mechanism behind it is not fully clear. Several possibilities are under investigation. Dr. Prokai-Tatrai said her translational research focuses on neuroprotection, not the mechanism that causes the elevated pressure.

“Our goal is to prevent neuron death using the eye drops, because once those neurons die they are gone forever,” she said. “Our preliminary data is unprecedented and very promising in terms of preserving visual acuity.

“This gives us hope, that if the approach is successful, we can develop a complementary therapy used together with conventional medications for those with glaucoma.”

The multidisciplinary research involves medicinal chemistry-driven drug discovery and delivery, retina proteomics and ophthalmology and is in collaboration with other researchers at UNTHSC and at the University of Missouri-Kansas City School of Medicine.

Es Fc
Study links preventable diabetes hospitalizations to behavioral health

By Sally Crocker A new study by UNTHSC public health researchers points to important information that may help health care providers, policymakers and insurance payers reduce the risk of preventable hospitalizations for diabetes patients. The study in PLOS ONE provides insight into the rel...Read more

Mar 25, 2019

Pharm Fc
Pharmacy students travel to Austin for lesson in advocacy

By Jan Jarvis    Nearly a quarter of UNT System College of Pharmacy students took a day off from their classes to get a lesson in advocacy.  The students joined nearly 600 pharmacy professionals from throughout the state for Pharmacist Day at the Capitol in Austin. The Texas Pharma...Read more

Mar 21, 2019

Art Fc
Young artists exhibit their work in Atrium Gallery this spring

By Rebecca Najera High school juniors and seniors have the chance to show off their artistic skills at the UNT Health Science Center when the annual High School Art Show opens in the Atrium Gallery April 5. Brock ISD art teacher Sue Brunner has been submitting her students’ work to the art s...Read more

Mar 20, 2019

Team Fc
UNTHSC helps United Way of Tarrant County outline future direction

By Sally Crocker   A team of UNTHSC researchers has recently completed a comprehensive community assessment for United Way of Tarrant County that will help set the organization’s strategic direction for years to come. Findings from this extensive study, which uncovered some of the m...Read more

Mar 19, 2019